Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02029690 · ClinicalTrials.gov registry record · Phase 1
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
A Phase 1 study, sponsored by Polaris Group.
- Terminated
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT02029690 is a Phase 1 study that was terminated before completion, run by Polaris Group. The registered enrollment target is 85 participants.
The verdict
NCT02029690, a Phase 1 study, was terminated before completion, sponsored by Polaris Group.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort only), non-squamous non-small cell lung carcinoma stage IIIB/IV (NSCLC), metastatic uveal melanoma, hepatocellular carcinoma (HCC), glioma and sarcomatoid cancers
Interventions
- DRUG ADI-PEG 20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2014-04-23 |
| Est. Completion | 2020-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02029690
The ClinicalTrials.gov registry entry for NCT02029690 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Polaris Group, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADI-PEG 20 is the first listed.
NCT02029690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02029690 about?
NCT02029690 is a clinical study titled "Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin". A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort only), non-squamous non-small cell lung carcinoma stage IIIB/IV (NSCLC)...
What is the current status of trial NCT02029690?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2014-04-23. Estimated completion is 2020-06.
What interventions are being tested in trial NCT02029690?
The interventions under investigation include: ADI-PEG 20 (DRUG).
Who is sponsoring clinical trial NCT02029690?
This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.